191 related articles for article (PubMed ID: 27458164)
1. Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling.
Moharram SA; Chougule RA; Su X; Li T; Sun J; Zhao H; Rönnstrand L; Kazi JU
Oncotarget; 2016 Sep; 7(36):57770-57782. PubMed ID: 27458164
[TBL] [Abstract][Full Text] [Related]
2. BEX1 acts as a tumor suppressor in acute myeloid leukemia.
Lindblad O; Li T; Su X; Sun J; Kabir NN; Levander F; Zhao H; Lu G; Rönnstrand L; Kazi JU
Oncotarget; 2015 Aug; 6(25):21395-405. PubMed ID: 26046670
[TBL] [Abstract][Full Text] [Related]
3. ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling.
Kazi JU; Rupar K; Marhäll A; Moharram SA; Khanum F; Shah K; Gazi M; Nagaraj SR; Sun J; Chougule RA; Rönnstrand L
Oncotarget; 2017 Feb; 8(7):12194-12202. PubMed ID: 28086240
[TBL] [Abstract][Full Text] [Related]
4. Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling.
Kazi JU; Rönnstrand L
PLoS One; 2012; 7(12):e53509. PubMed ID: 23300935
[TBL] [Abstract][Full Text] [Related]
5. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Chougule RA; Kazi JU; Rönnstrand L
Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
[TBL] [Abstract][Full Text] [Related]
6. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.
Kazi JU; Rönnstrand L
Mol Oncol; 2013 Jun; 7(3):402-18. PubMed ID: 23246379
[TBL] [Abstract][Full Text] [Related]
7. Expression of GADS enhances FLT3-induced mitogenic signaling.
Chougule RA; Cordero E; Moharram SA; Pietras K; Rönnstrand L; Kazi JU
Oncotarget; 2016 Mar; 7(12):14112-24. PubMed ID: 26895103
[TBL] [Abstract][Full Text] [Related]
8. SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation.
Rupar K; Moharram SA; Kazi JU; Rönnstrand L
Sci Rep; 2018 Apr; 8(1):6405. PubMed ID: 29686302
[TBL] [Abstract][Full Text] [Related]
9. Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.
Lin DC; Yin T; Koren-Michowitz M; Ding LW; Gueller S; Gery S; Tabayashi T; Bergholz U; Kazi JU; Rönnstrand L; Stocking C; Koeffler HP
Blood; 2012 Oct; 120(16):3310-7. PubMed ID: 22942183
[TBL] [Abstract][Full Text] [Related]
10. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
Leischner H; Albers C; Grundler R; Razumovskaya E; Spiekermann K; Bohlander S; Rönnstrand L; Götze K; Peschel C; Duyster J
Blood; 2012 Apr; 119(17):4026-33. PubMed ID: 22411868
[TBL] [Abstract][Full Text] [Related]
11. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
12. SLAP2 Adaptor Binding Disrupts c-CBL Autoinhibition to Activate Ubiquitin Ligase Function.
Wybenga-Groot LE; Tench AJ; Simpson CD; Germain JS; Raught B; Moran MF; McGlade CJ
J Mol Biol; 2021 Apr; 433(8):166880. PubMed ID: 33617900
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of Src-like adaptor protein 2 reveals close association of SH3 and SH2 domains through β-sheet formation.
Wybenga-Groot LE; McGlade CJ
Cell Signal; 2013 Dec; 25(12):2702-8. PubMed ID: 24018043
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.
Kazi JU; Chougule RA; Li T; Su X; Moharram SA; Rupar K; Marhäll A; Gazi M; Sun J; Zhao H; Rönnstrand L
Cell Mol Life Sci; 2017 Jul; 74(14):2679-2688. PubMed ID: 28271164
[TBL] [Abstract][Full Text] [Related]
15. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
16. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
17. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
18. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
19. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
20. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.
Lopez S; Voisset E; Tisserand JC; Mosca C; Prebet T; Santamaria D; Dubreuil P; De Sepulveda P
Oncotarget; 2016 Aug; 7(32):51163-51173. PubMed ID: 27323399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
